LPS modulates rhinovirus-induced chemokine secretion in monocytes and macrophages.
Recent studies suggest that both bacteria and rhinoviruses (RVs) contribute to asthma exacerbations. We hypothesized that bacteria might alter antiviral responses early in the course of infection by modifying monocyte-lineage chemokine responses to RV infection. To test this hypothesis, human blood monocytes or bronchoalveolar lavage (BAL) macrophages were treated with RV types A016, B014, A001, and/or A002 in the presence or absence of LPS, and secretion of chemokines (CXCL10, CXCL11, CCL2, and CCL8) and IFN-α was measured by ELISA. Treatment with RV alone induced blood monocytes and BAL macrophages to secrete CXCL10, CXCL11, CCL2, and CCL8. Pretreatment with LPS significantly attenuated RV-induced CXCL10, CXCL11, and CCL8 secretion by 68-99.9% on average (P < 0.0001, P < 0.004, and P < 0.002, respectively), but did not inhibit RV-induced CCL2 from blood monocytes. Similarly, LPS inhibited RV-induced CXCL10 and CXCL11 secretion by over 88% on average from BAL macrophages (P < 0.002 and P < 0.0001, respectively). Furthermore, LPS inhibited RV-induced signal transducer and activator of transcription 1 phosphorylation (P < 0.05), as determined by immunoblotting, yet augmented RV-induced IFN-α secretion (P < 0.05), and did not diminish expression of RV target receptors, as measured by flow cytometry. In summary, major and minor group RVs strongly induce chemokine expression and IFN-α from monocytic cells. The bacterial product, LPS, specifically inhibits monocyte and macrophage secretion of RV-induced CXCL10 and CXCL11, but not other highly induced chemokines or IFN-α. These effects suggest that airway bacteria could modulate the pattern of virus-induced cell recruitment and inflammation in the airways.
1 Molecular and Cellular Pharmacology Graduate Program, and.
Maya R
MR
Karta
Monica L
ML
Gavala
Colleen S
CS
Curran
Lisa E
LE
Wickert
Patricia J
PJ
Keely
James E
JE
Gern
Paul J
PJ
Bertics
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D018893:Bronchoalveolar Lavage; D018925:Chemokines / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D004847:Epithelial Cells; D005260:Female; D006801:Humans; D015151:Immunoblotting; D007249:Inflammation / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology / Q000821:virology; D010850:Picornaviridae Infections / Q000150:complications / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D012229:Rhinovirus / Q000472:pathogenicity*; D055815:Young Adult
D018925:Chemokines; D008070:Lipopolysaccharides
LPS; chemokines; macrophages; monocytes; rhinovirus